{"id":23,"date":"2023-11-27T11:29:27","date_gmt":"2023-11-27T11:29:27","guid":{"rendered":"https:\/\/www.ipsen.com\/de\/?page_id=23"},"modified":"2024-10-10T13:10:58","modified_gmt":"2024-10-10T11:10:58","slug":"home","status":"publish","type":"page","link":"https:\/\/www.ipsen.com\/germany\/","title":{"rendered":"Home"},"content":{"rendered":"\t<!-- Hero Carousel Start Here-->\n\t<section class=\"hero-section blue-filter\">\n\t\t<div class=\"hero_fullwidth \"><!-- container class shown if gridlayout choosen -->\n\t\t\t<div id=\"heroCarousel\" class=\"carousel slide herocaro hero-banner-bg-image\" data-bs-ride=\"carousel\" data-enableplaybtn=\"\" data-autoplay= \"1\"  data-autospeed= \"5000\" >\n\t\t\t\t<!-- Slider Indicator-->\n\t\t\t\t<div class=\"carousel-indicators visible\">\n\t\t\t\t<button type=\"button\" data-bs-target=\"#heroCarousel\" data-bs-slide-to=\"0\" class=\"active\" aria-current=\"true\" aria-label=\"Slide 0\"><\/button><button type=\"button\" data-bs-target=\"#heroCarousel\" data-bs-slide-to=\"1\" class=\"\" aria-current=\"true\" aria-label=\"Slide 1\"><\/button><button type=\"button\" data-bs-target=\"#heroCarousel\" data-bs-slide-to=\"2\" class=\"\" aria-current=\"true\" aria-label=\"Slide 2\"><\/button>\t\t\t\t<\/div>\n\t\t\t\t<!-- Items -->\n\t\t\t\t<div class=\"carousel-inner\">\n\t\t\t\t\t\t\n\t\t\t\t\t\t<!-- Hero Banner with carousel HTML -->\n\t\t\t\t\t\t<div class=\"carousel-item active\">\n\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<img decoding=\"async\" class=\"bd-placeholder-img visible mobile-view\" width=\"100%\" height=\"100%\" src=\"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/sites\/6\/2023\/11\/29061147\/FTFPS_HERO_Banner_1920x720.png\" aria-hidden=\"true\" title=\"Hero Banner Video Image\" alt=\"Hero Banner Video Image\" \/> \n\t\t\t\t\t\t\t\t\t\t<div class=\"video visible desktop-view\"> \n\t\t\t\t\t\t\t\t\t\t\t<div class='embed-container'> \n\t\t\t\t\t\t\t\t\t\t\t\t<div style=\"padding:73%;\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t<iframe loading=\"lazy\" title=\"Corporate video for Ipsen.com Carousel\" src=\"https:\/\/player.vimeo.com\/video\/907805951?h=ae8a3a1d3a&amp;app_id=122963&#038;autoplay=1&#038;muted=1&#038;controls=0&#038;loop=1&#038;autopause=1\" width=\"640\" height=\"360\" frameborder=\"0\" allow=\"autoplay; fullscreen; picture-in-picture; clipboard-write\" frameborder=\"0\" allow=\"autoplay; fullscreen; picture-in-picture\" data-ot-ignore><\/iframe>\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t<\/div>\t\n\n\t\t\t\t\t\t\t\t\n\n\t\t\t\t\t\t\t<div class=\"container align-left\">\n\t\t\t\t\t\t\t\t<div class=\"carousel-caption\">\n\t\t\t\t\t\t\t\t\t<h2 class=\"visible text-start\">Focus. Together. For patients and society.<\/h2>\n\t\t\t\t\t\t\t\t\t<div class=\"visible text-start\">Wir bei Ipsen entwickeln innovative Arzneimittel f\u00fcr Menschen mit schweren oder seltenen Erkrankungen, f\u00fcr die ein hoher, nicht gedeckter medizinischer Bedarf besteht. <\/div>\n\t\t\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<p class=\"visible text-start\">\n\t\t\t\t\t\t\t\t\t\t\t<a class=\"btn btn-lg btn-primary\" href=\"\/germany\/ueber-uns\/\" target=\"\">\n\t\t\t\t\t\t\t\t\t\t\t\tUnsere Strategie \t\t\t\t\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t<\/p>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\n\t\t\t\t\t\t\n\t\t\t\t\t\t<!-- Hero Banner with carousel HTML -->\n\t\t\t\t\t\t<div class=\"carousel-item \">\n\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<img decoding=\"async\" class=\"bd-placeholder-img visible\" width=\"100%\" height=\"100%\" src=\"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/sites\/6\/2023\/11\/28113146\/01-4_Hero-image_Bath-road-UK-img-03-none_R_1980x720pix.jpg\" aria-hidden=\"true\" title=\"Hero Banner\" alt=\"Hero Banner\" \/> \n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\t\n\n\t\t\t\t\t\t\t<div class=\"container align-left\">\n\t\t\t\t\t\t\t\t<div class=\"carousel-caption\">\n\t\t\t\t\t\t\t\t\t<h2 class=\"visible text-start\">Ipsen Way of Being<\/h2>\n\t\t\t\t\t\t\t\t\t<div class=\"visible text-start\">Tagt\u00e4glich engagieren wir uns gemeinsam f\u00fcr die bessere Versorgung unserer Patient*innen: F\u00fcr ein  l\u00e4ngeres Leben und mehr Lebensqualit\u00e4t.  <\/div>\n\t\t\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<p class=\"visible text-start\">\n\t\t\t\t\t\t\t\t\t\t\t<a class=\"btn btn-lg btn-primary\" href=\"\/germany\/verantwortung\/\" target=\"\">\n\t\t\t\t\t\t\t\t\t\t\t\tMehr erfahren \t\t\t\t\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t<\/p>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\n\t\t\t\t\t\t\n\t\t\t\t\t\t<!-- Hero Banner with carousel HTML -->\n\t\t\t\t\t\t<div class=\"carousel-item \">\n\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<img decoding=\"async\" class=\"bd-placeholder-img visible\" width=\"100%\" height=\"100%\" src=\"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/sites\/6\/2023\/11\/28113223\/01-3_Hero-image_Ipsen_Site_Ulis_018-1.jpg\" aria-hidden=\"true\" title=\"Hero Banner\" alt=\"Hero Banner\" \/> \n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\t\n\n\t\t\t\t\t\t\t<div class=\"container align-left\">\n\t\t\t\t\t\t\t\t<div class=\"carousel-caption\">\n\t\t\t\t\t\t\t\t\t<h2 class=\"visible text-start\">Lebensver\u00e4ndernde innovative Arzneimittel<\/h2>\n\t\t\t\t\t\t\t\t\t<div class=\"visible text-start\">Wir bei Ipsen treiben die Entwicklung therapeutischer L\u00f6sungen voran, um Menschen mit schweren oder seltenen Erkrankungen innovative Behandlungen und Therapieoptionen zu erm\u00f6glichen. <\/div>\n\t\t\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<p class=\"visible text-start\">\n\t\t\t\t\t\t\t\t\t\t\t<a class=\"btn btn-lg btn-primary\" href=\"\/germany\/forschung-entwicklung\/\" target=\"\">\n\t\t\t\t\t\t\t\t\t\t\t\tMehr erfahren \t\t\t\t\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t<\/p>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\n\t\t\t\t\t\t\t\t\t<\/div>\n\n\t\t\t\t\t\t\t\t\t<button class=\"carousel-control-prev visible\" aria-label=\"previous\" aria-labelledby=\"carousel-control-prev\" role=\"button\" type=\"button\" title=\"previous\" data-bs-target=\"#heroCarousel\" data-bs-slide=\"prev\">\n\t\t\t\t\t\t<span class=\"carousel-control-prev-icon\" aria-hidden=\"true\"><\/span>\n\t\t\t\t\t<\/button>\n\t\t\t\t\t<button class=\"carousel-control-next visible\" aria-label=\"next\" aria-labelledby=\"carousel-control-next\" role=\"button\" type=\"button\" title=\"next\" type=\"button\" data-bs-target=\"#heroCarousel\" data-bs-slide=\"next\">\n\t\t\t\t\t\t<span class=\"carousel-control-next-icon\" aria-hidden=\"true\"><\/span>\n\t\t\t\t\t<\/button>\n\t\t\t\t\n\t\t\t\t\n\t\t\t<\/div>\n\t\t<\/div>\n\t<\/section>\n\t<!-- Hero Carousel End Here-->\n  \n\n    <section class=\"title-text \">\n        <div class=\"container\">\n            <div class=\"title-text-inner\" style=\"background-color:#DBEAF5;\">\n                <!-- If heading is enabled then it's visible -->\n                <div class=\"text-head-dash visible\">\n                                            <span class=\"dash\"><\/span> \n                        <p class=\"heading-para\">\n                            \u00dcber Ipsen                         <\/p>\n                                        \n                <\/div>\n\n                <!-- If subtitle is enabled then it's visible -->\n                <div class=\"text-head-dash hidden\">\n                                            <h2 class=\"heading-para\">\n                                                    <\/h2>\n                    \n                <\/div>\n                \n                <!-- If description is enabled then it's visible -->\n                <div class=\"text-parbase visible\">\n                    <p><p><span class=\"TextRun SCXW110622614 BCX0\" lang=\"DE-DE\" xml:lang=\"DE-DE\" data-contrast=\"auto\"><span class=\"NormalTextRun SCXW110622614 BCX0\">Ipsen ist ein <\/span><span class=\"NormalTextRun SCXW110622614 BCX0\">mitte<\/span><span class=\"NormalTextRun SCXW110622614 BCX0\">lst\u00e4ndisches<\/span><span class=\"NormalTextRun SCXW110622614 BCX0\">, <\/span><span class=\"NormalTextRun SCXW110622614 BCX0\">global<\/span><span class=\"NormalTextRun SCXW110622614 BCX0\"> t\u00e4tiges <\/span><span class=\"NormalTextRun SCXW110622614 BCX0\">Biopharmau<\/span><span class=\"NormalTextRun SCXW110622614 BCX0\">nternehmen<\/span><span class=\"NormalTextRun SCXW110622614 BCX0\">, das spezialisiert ist auf die Entwicklung innovativer Arzneimittel f\u00fcr Menschen, die an onkologischen, neurologischen oder seltenen Erkrankungen leiden. Patient<\/span><span class=\"NormalTextRun SCXW110622614 BCX0\">*<\/span><span class=\"NormalTextRun SCXW110622614 BCX0\">innen <\/span><span class=\"NormalTextRun SCXW110622614 BCX0\">auf<\/span><span class=\"NormalTextRun SCXW110622614 BCX0\"> der ganzen Welt profitieren vom therapeutischen Potenzial unserer medizinischen L\u00f6sungen f\u00fcr ein besseres Leben<\/span><span class=\"NormalTextRun SCXW110622614 BCX0\"> und mehr Lebensqualit\u00e4t<\/span><span class=\"NormalTextRun SCXW110622614 BCX0\">.<\/span><\/span><span class=\"EOP SCXW110622614 BCX0\" data-ccp-props=\"{}\">\u00a0<\/span><\/p>\n<\/p>\n                <\/div>\n\n                <!-- If button is enabled then it's visible -->\n                \n            <\/div>\n        <\/div>\n    <\/section>\n\n\n<!-- Text & Media Block Code -->\n<section class=\"two-col-section text-media-section\">\n    <div class=\"container two-section-innner \">\n        <div class=\"response-inner\" style=\"background-image: url('')\">\n            <div class=\"row \">\n                <div class=\"col-xs-12 col-sm-12 col-md-6\">\n                                                    <div class=\"img-video-section\">\n                                <img decoding=\"async\" src=\"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/sites\/6\/2023\/11\/28135332\/02_WhatWeDo_DSA01946-1.png\" alt=\"Was wir tun  \" title=\"Was wir tun  \">\n                            <\/div>\n                                        <\/div>\n                <div class=\" col-xs-12 col-sm-12 col-md-6\">\n                    <div class=\"section-content\">\n                        <div class=\"heading-dash\">\n                                                                <span class=\"dash\"><\/span>\n                                <p class=\"heading-para\">\n                                    Was wir tun                                  <\/p>\n                                                    <\/div>\n                        <p class=\"section-head-two\">\n                                                    <\/p>\n                        <p><span class=\"TextRun SCXW133998205 BCX0\" lang=\"DE-DE\" xml:lang=\"DE-DE\" data-contrast=\"auto\"><span class=\"NormalTextRun SCXW133998205 BCX0\">Fortschritt ist unser Ansporn. <\/span><span class=\"NormalTextRun SCXW133998205 BCX0\">Um bestehende Versorgungsl\u00fccken zu schlie\u00dfen, konzentrieren wir uns bei Ipsen b<\/span><span class=\"NormalTextRun SCXW133998205 BCX0\">ei der Entwicklung <\/span><span class=\"NormalTextRun SCXW133998205 BCX0\">unserer innovativen Arzneimittel<\/span> <span class=\"NormalTextRun SCXW133998205 BCX0\">auf Bereiche <\/span><span class=\"NormalTextRun ContextualSpellingAndGrammarErrorV2Themed SCXW133998205 BCX0\">mit hohem <\/span><span class=\"NormalTextRun ContextualSpellingAndGrammarErrorV2Themed SCXW133998205 BCX0\">ungedeckten<\/span><span class=\"NormalTextRun ContextualSpellingAndGrammarErrorV2Themed SCXW133998205 BCX0\"> medizinische<\/span><span class=\"NormalTextRun ContextualSpellingAndGrammarErrorV2Themed SCXW133998205 BCX0\">n<\/span><span class=\"NormalTextRun ContextualSpellingAndGrammarErrorV2Themed SCXW133998205 BCX0\"> Bedarf<\/span><span class=\"NormalTextRun SCXW133998205 BCX0\">.<\/span> <span class=\"NormalTextRun SCXW133998205 BCX0\">Konsequent ausgerichtet an den therapeutischen Notwendigkeiten <\/span><span class=\"NormalTextRun ContextualSpellingAndGrammarErrorV2Themed SCXW133998205 BCX0\">unserer Patient<\/span><span class=\"NormalTextRun SCXW133998205 BCX0\">*<\/span><span class=\"NormalTextRun SCXW133998205 BCX0\">innen bauen wir <\/span><span class=\"NormalTextRun SCXW133998205 BCX0\">unsere Pipeline <\/span><span class=\"NormalTextRun SCXW133998205 BCX0\">kontinuierlich und dynamisch <\/span><span class=\"NormalTextRun SCXW133998205 BCX0\">aus<\/span><span class=\"NormalTextRun SCXW133998205 BCX0\">.<\/span><\/span><span class=\"EOP SCXW133998205 BCX0\" data-ccp-props=\"{}\">\u00a0<\/span><\/p>\n                            \n                        <button aria-label=\"Learn more about Was wir tun  \" role=\"link\" class=\"btn-link section-btn cta-visible\"> \n                            <a aria-label=\"Learn more about\" href=\"\/germany\/forschung-entwicklung\/\" target=\"_self\"> Mehr erfahren  <\/a>\n                        <\/button>\n                        \n                    <\/div>\n                <\/div>\n            <\/div>\n        <\/div>\n    <\/div>\n<\/section>\n\n\n\n\n    <section class=\"slim-card blue-bg left\">\n        <div class=\"container\">\n          <div class=\"slim-card-inner\">\n                         <div class=\"slim-standard-section\">\n    <div class=\"slim-standard-section-inner\">\n        <div class=\"row normal-div\">\n                            <div class=\"column-1 col-xl-3 col-md-12 col-sm-12 with-carousel\">\n                    <div class=\"slim-standard-heading-div\">\n                        <h2 class=\"charcoal-grey visible\">Aktuelle Highlights von Ipsen <\/h2>\n                        <p class=\"slim-standard-para charcoal-grey visible\"> Presseinformationen, Trending Stories, Events und mehr <\/p>\n                    <\/div>\n                <\/div>\n            \n            <div class=\"column-2 col-xl-9 col-md-12 col-sm-12\">\n                <!-- slim-standard carousel -->\n                <div class=\"slim-standard-carousel multiple\">\n                    <div class=\"glider-contain\">\n                                                    <div class=\"slim-standard-content-btn\">\n                                <button aria-label=\"Previous\" class=\"glider-slim-standard-prev disabled\" aria-disabled=\"true\">\n                                    <span><\/span>\n                                <\/button>\n                                <button aria-label=\"Next\" class=\"glider-slim-standard-next\" aria-disabled=\"false\">\n                                    <span><\/span>\n                                <\/button>\n                            <\/div>\n                        \n                        <div class=\"glider-slim-standard\">\n                                                            <div class=\"slim-standard-tab glider-slide left-0\" data-gslide=\"0 active visible\" tab-index=\"0\">\n                                    <div class=\"highligth-row\">\n                                        <a href=\"https:\/\/www.ipsen.com\/germany\/press-releases\/ipsen-erhalt-eu-zulassung-fur-iqirvo-elafibranor-als-erste-neue-therapie-fur-primar-biliare-cholangitis-pbc-seit-fast-einem-jahrzehnt\/\"  aria-label=\"Ipsen erh\u00e4lt EU-Zulassung f\u00fcr IQIRVO\u00ae (Elafibranor) als erste neue Therapie f\u00fcr prim\u00e4r bili\u00e4re Cholangitis (PBC)...\">\n                                            <div class=\"column-1\">\n                                                <div class=\"slim-standard-img\">\n                                                                                                                <a href=\"https:\/\/www.ipsen.com\/germany\/press-releases\/ipsen-erhalt-eu-zulassung-fur-iqirvo-elafibranor-als-erste-neue-therapie-fur-primar-biliare-cholangitis-pbc-seit-fast-einem-jahrzehnt\/\" >\n                                                                <img decoding=\"async\" src=\"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/sites\/6\/2023\/12\/06080352\/PR-final.jpg\" aria-label=\"Ipsen erh\u00e4lt EU-Zulassung f\u00fcr IQIRVO\u00ae (Elafibranor) als erste neue Therapie f\u00fcr prim\u00e4r bili\u00e4re Cholangitis (PBC)...\" title=\"Ipsen erh\u00e4lt EU-Zulassung f\u00fcr IQIRVO\u00ae (Elafibranor) als erste neue Therapie f\u00fcr prim\u00e4r bili\u00e4re Cholangitis (PBC)...\" >\n                                                            <\/a>\n                                                        \n                                                <\/div>\n                                            <\/div>\n                                        <\/a>\n                                        <a href=\"https:\/\/www.ipsen.com\/germany\/press-releases\/ipsen-erhalt-eu-zulassung-fur-iqirvo-elafibranor-als-erste-neue-therapie-fur-primar-biliare-cholangitis-pbc-seit-fast-einem-jahrzehnt\/\"  aria-label=\"Ipsen erh\u00e4lt EU-Zulassung f\u00fcr IQIRVO\u00ae (Elafibranor) als erste neue Therapie f\u00fcr prim\u00e4r bili\u00e4re Cholangitis (PBC)...\">\n                                            <div class=\"column-2\">\n                                                <div class=\"slim-standard-content\">\n                                                    <div class=\"slim-standard-tab-sec\">\n                                                        <button class=\"btn small-btn grey-bg visible\" style=\"background-color:#7dc1e5;\"> Seltene Erkrankungen <\/button>\n                                                        <p class=\"date-time dark-grey visible\">  &#8211; 08 Oktober 2024 <\/p>\n                                                    <\/div>\n                                                    <div class=\"slim-standard-para-sec\">\n                                                        <p class=\"slim-standard-para primary-blue\">\n                                                            Ipsen erh\u00e4lt EU-Zulassung f\u00fcr IQIRVO\u00ae (Elafibranor) als erste neue Therapie f\u00fcr prim\u00e4r bili\u00e4re Cholangitis (PBC)&#8230;                                                        <\/p>\n                                                    <\/div>\n                                                <\/div>\n                                            <\/div>\n                                        <\/a>\n\n                                        <\/div>\n                                <\/div>\n                                                        <div class=\"slim-standard-tab glider-slide left-1\" data-gslide=\"1  \" tab-index=\"0\">\n                                    <div class=\"highligth-row\">\n                                        <a href=\"https:\/\/www.ipsen.com\/germany\/press-releases\/ipsen-erhebt-verfassungsbeschwerde-gegen-gkv-finstg-und-albvvg\/\"  aria-label=\"Ipsen erhebt Verfassungsbeschwerde gegen GKV-FinStG und ALBVVG\">\n                                            <div class=\"column-1\">\n                                                <div class=\"slim-standard-img\">\n                                                                                                                <a href=\"https:\/\/www.ipsen.com\/germany\/press-releases\/ipsen-erhebt-verfassungsbeschwerde-gegen-gkv-finstg-und-albvvg\/\" >\n                                                                <img decoding=\"async\" src=\"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/sites\/6\/2023\/12\/06080352\/PR-final.jpg\" aria-label=\"Ipsen erhebt Verfassungsbeschwerde gegen GKV-FinStG und ALBVVG\" title=\"Ipsen erhebt Verfassungsbeschwerde gegen GKV-FinStG und ALBVVG\" >\n                                                            <\/a>\n                                                        \n                                                <\/div>\n                                            <\/div>\n                                        <\/a>\n                                        <a href=\"https:\/\/www.ipsen.com\/germany\/press-releases\/ipsen-erhebt-verfassungsbeschwerde-gegen-gkv-finstg-und-albvvg\/\"  aria-label=\"Ipsen erhebt Verfassungsbeschwerde gegen GKV-FinStG und ALBVVG\">\n                                            <div class=\"column-2\">\n                                                <div class=\"slim-standard-content\">\n                                                    <div class=\"slim-standard-tab-sec\">\n                                                        <button class=\"btn small-btn grey-bg visible\" style=\"background-color:#5d6265;\"> Company <\/button>\n                                                        <p class=\"date-time dark-grey visible\">  &#8211; 16 November 2023 <\/p>\n                                                    <\/div>\n                                                    <div class=\"slim-standard-para-sec\">\n                                                        <p class=\"slim-standard-para primary-blue\">\n                                                            Ipsen erhebt Verfassungsbeschwerde gegen GKV-FinStG und ALBVVG                                                        <\/p>\n                                                    <\/div>\n                                                <\/div>\n                                            <\/div>\n                                        <\/a>\n\n                                        <\/div>\n                                <\/div>\n                                                        <div class=\"slim-standard-tab glider-slide left-2\" data-gslide=\"2  \" tab-index=\"0\">\n                                    <div class=\"highligth-row\">\n                                        <a href=\"https:\/\/www.ipsen.com\/germany\/press-releases\/off-label-anwendung-von-botulinumtoxin\/\"  aria-label=\"Off-label Anwendung von Botulinumtoxin\">\n                                            <div class=\"column-1\">\n                                                <div class=\"slim-standard-img\">\n                                                                                                                <a href=\"https:\/\/www.ipsen.com\/germany\/press-releases\/off-label-anwendung-von-botulinumtoxin\/\" >\n                                                                <img decoding=\"async\" src=\"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/sites\/6\/2023\/12\/06080352\/PR-final.jpg\" aria-label=\"Off-label Anwendung von Botulinumtoxin\" title=\"Off-label Anwendung von Botulinumtoxin\" >\n                                                            <\/a>\n                                                        \n                                                <\/div>\n                                            <\/div>\n                                        <\/a>\n                                        <a href=\"https:\/\/www.ipsen.com\/germany\/press-releases\/off-label-anwendung-von-botulinumtoxin\/\"  aria-label=\"Off-label Anwendung von Botulinumtoxin\">\n                                            <div class=\"column-2\">\n                                                <div class=\"slim-standard-content\">\n                                                    <div class=\"slim-standard-tab-sec\">\n                                                        <button class=\"btn small-btn grey-bg visible\" style=\"background-color:#a9d5ed;\"> Neurologie <\/button>\n                                                        <p class=\"date-time dark-grey visible\">  &#8211; 28 M\u00e4rz 2023 <\/p>\n                                                    <\/div>\n                                                    <div class=\"slim-standard-para-sec\">\n                                                        <p class=\"slim-standard-para primary-blue\">\n                                                            Off-label Anwendung von Botulinumtoxin                                                        <\/p>\n                                                    <\/div>\n                                                <\/div>\n                                            <\/div>\n                                        <\/a>\n\n                                        <\/div>\n                                <\/div>\n                                                        <div class=\"slim-standard-tab glider-slide left-3\" data-gslide=\"3  \" tab-index=\"0\">\n                                    <div class=\"highligth-row\">\n                                        <a href=\"https:\/\/www.ipsen.com\/germany\/?post_type=press_release&#038;p=2160\"  aria-label=\"Metastasiertes kastrationsresistentes Prostatakarzinom: Erste Ergebnisse der Phase-III-Studie CONTACT-02 zeigen verl\u00e4ngertes PFS beim mCRPC unter Kombinationstherapie...\">\n                                            <div class=\"column-1\">\n                                                <div class=\"slim-standard-img\">\n                                                                                                                <a href=\"https:\/\/www.ipsen.com\/germany\/?post_type=press_release&#038;p=2160\" >\n                                                                <img decoding=\"async\" src=\"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/sites\/6\/2023\/12\/06080352\/PR-final.jpg\" aria-label=\"Metastasiertes kastrationsresistentes Prostatakarzinom: Erste Ergebnisse der Phase-III-Studie CONTACT-02 zeigen verl\u00e4ngertes PFS beim mCRPC unter Kombinationstherapie...\" title=\"Metastasiertes kastrationsresistentes Prostatakarzinom: Erste Ergebnisse der Phase-III-Studie CONTACT-02 zeigen verl\u00e4ngertes PFS beim mCRPC unter Kombinationstherapie...\" >\n                                                            <\/a>\n                                                        \n                                                <\/div>\n                                            <\/div>\n                                        <\/a>\n                                        <a href=\"https:\/\/www.ipsen.com\/germany\/?post_type=press_release&#038;p=2160\"  aria-label=\"Metastasiertes kastrationsresistentes Prostatakarzinom: Erste Ergebnisse der Phase-III-Studie CONTACT-02 zeigen verl\u00e4ngertes PFS beim mCRPC unter Kombinationstherapie...\">\n                                            <div class=\"column-2\">\n                                                <div class=\"slim-standard-content\">\n                                                    <div class=\"slim-standard-tab-sec\">\n                                                        <button class=\"btn small-btn grey-bg visible\" style=\"background-color:#2797d3;\"> Onkologie <\/button>\n                                                        <p class=\"date-time dark-grey visible\">  &#8211; 13 M\u00e4rz 2024 <\/p>\n                                                    <\/div>\n                                                    <div class=\"slim-standard-para-sec\">\n                                                        <p class=\"slim-standard-para primary-blue\">\n                                                            Metastasiertes kastrationsresistentes Prostatakarzinom: Erste Ergebnisse der Phase-III-Studie CONTACT-02 zeigen verl\u00e4ngertes PFS beim mCRPC unter Kombinationstherapie&#8230;                                                        <\/p>\n                                                    <\/div>\n                                                <\/div>\n                                            <\/div>\n                                        <\/a>\n\n                                        <\/div>\n                                <\/div>\n                                                        <div class=\"slim-standard-tab glider-slide left-4\" data-gslide=\"4  \" tab-index=\"0\">\n                                    <div class=\"highligth-row\">\n                                        <a href=\"https:\/\/www.ipsen.com\/germany\/press-releases\/ipsen-ab-sofort-mit-eigenen-niederlassungen-in-oesterreich-und-in-der-schweiz-vertreten-zwei-standorte-fuer-den-direkten-kontakt-zu-anderen-akteuren-im-gesundheitswesen-und-mit-starken-teams\/\"  aria-label=\"Ipsen ab sofort mit eigenen Niederlassungen in \u00d6sterreich und in der Schweiz vertreten \u2013 zwei...\">\n                                            <div class=\"column-1\">\n                                                <div class=\"slim-standard-img\">\n                                                                                                                <a href=\"https:\/\/www.ipsen.com\/germany\/press-releases\/ipsen-ab-sofort-mit-eigenen-niederlassungen-in-oesterreich-und-in-der-schweiz-vertreten-zwei-standorte-fuer-den-direkten-kontakt-zu-anderen-akteuren-im-gesundheitswesen-und-mit-starken-teams\/\" >\n                                                                <img decoding=\"async\" src=\"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/sites\/6\/2023\/12\/06080352\/PR-final.jpg\" aria-label=\"Ipsen ab sofort mit eigenen Niederlassungen in \u00d6sterreich und in der Schweiz vertreten \u2013 zwei...\" title=\"Ipsen ab sofort mit eigenen Niederlassungen in \u00d6sterreich und in der Schweiz vertreten \u2013 zwei...\" >\n                                                            <\/a>\n                                                        \n                                                <\/div>\n                                            <\/div>\n                                        <\/a>\n                                        <a href=\"https:\/\/www.ipsen.com\/germany\/press-releases\/ipsen-ab-sofort-mit-eigenen-niederlassungen-in-oesterreich-und-in-der-schweiz-vertreten-zwei-standorte-fuer-den-direkten-kontakt-zu-anderen-akteuren-im-gesundheitswesen-und-mit-starken-teams\/\"  aria-label=\"Ipsen ab sofort mit eigenen Niederlassungen in \u00d6sterreich und in der Schweiz vertreten \u2013 zwei...\">\n                                            <div class=\"column-2\">\n                                                <div class=\"slim-standard-content\">\n                                                    <div class=\"slim-standard-tab-sec\">\n                                                        <button class=\"btn small-btn grey-bg visible\" style=\"background-color:#5d6265;\"> Company <\/button>\n                                                        <p class=\"date-time dark-grey visible\">  &#8211; 12 August 2022 <\/p>\n                                                    <\/div>\n                                                    <div class=\"slim-standard-para-sec\">\n                                                        <p class=\"slim-standard-para primary-blue\">\n                                                            Ipsen ab sofort mit eigenen Niederlassungen in \u00d6sterreich und in der Schweiz vertreten \u2013 zwei&#8230;                                                        <\/p>\n                                                    <\/div>\n                                                <\/div>\n                                            <\/div>\n                                        <\/a>\n\n                                        <\/div>\n                                <\/div>\n                                                        <div class=\"slim-standard-tab glider-slide left-5\" data-gslide=\"5  \" tab-index=\"0\">\n                                    <div class=\"highligth-row\">\n                                        <a href=\"https:\/\/www.ipsen.com\/germany\/press-releases\/enets-2022-aktuelle-ergebnisse-aus-patientenstudien-zur-ssa-therapiehohes-mass-an-zufriedenheit-und-weniger-schmerzen-an-einstichstelle-mit-lan-fertigspritze\/\"  aria-label=\"ENETS 2022: Aktuelle Ergebnisse aus Patientenstudien zur SSA-Therapie: Hohes Ma\u00df an Zufriedenheit und weniger Schmerzen...\">\n                                            <div class=\"column-1\">\n                                                <div class=\"slim-standard-img\">\n                                                                                                                <a href=\"https:\/\/www.ipsen.com\/germany\/press-releases\/enets-2022-aktuelle-ergebnisse-aus-patientenstudien-zur-ssa-therapiehohes-mass-an-zufriedenheit-und-weniger-schmerzen-an-einstichstelle-mit-lan-fertigspritze\/\" >\n                                                                <img decoding=\"async\" src=\"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/sites\/6\/2023\/12\/06080352\/PR-final.jpg\" aria-label=\"ENETS 2022: Aktuelle Ergebnisse aus Patientenstudien zur SSA-Therapie: Hohes Ma\u00df an Zufriedenheit und weniger Schmerzen...\" title=\"ENETS 2022: Aktuelle Ergebnisse aus Patientenstudien zur SSA-Therapie: Hohes Ma\u00df an Zufriedenheit und weniger Schmerzen...\" >\n                                                            <\/a>\n                                                        \n                                                <\/div>\n                                            <\/div>\n                                        <\/a>\n                                        <a href=\"https:\/\/www.ipsen.com\/germany\/press-releases\/enets-2022-aktuelle-ergebnisse-aus-patientenstudien-zur-ssa-therapiehohes-mass-an-zufriedenheit-und-weniger-schmerzen-an-einstichstelle-mit-lan-fertigspritze\/\"  aria-label=\"ENETS 2022: Aktuelle Ergebnisse aus Patientenstudien zur SSA-Therapie: Hohes Ma\u00df an Zufriedenheit und weniger Schmerzen...\">\n                                            <div class=\"column-2\">\n                                                <div class=\"slim-standard-content\">\n                                                    <div class=\"slim-standard-tab-sec\">\n                                                        <button class=\"btn small-btn grey-bg visible\" style=\"background-color:#2797d3;\"> Onkologie <\/button>\n                                                        <p class=\"date-time dark-grey visible\">  &#8211; 22 M\u00e4rz 2022 <\/p>\n                                                    <\/div>\n                                                    <div class=\"slim-standard-para-sec\">\n                                                        <p class=\"slim-standard-para primary-blue\">\n                                                            ENETS 2022: Aktuelle Ergebnisse aus Patientenstudien zur SSA-Therapie: Hohes Ma\u00df an Zufriedenheit und weniger Schmerzen&#8230;                                                        <\/p>\n                                                    <\/div>\n                                                <\/div>\n                                            <\/div>\n                                        <\/a>\n\n                                        <\/div>\n                                <\/div>\n                                                        <div class=\"slim-standard-tab glider-slide left-6\" data-gslide=\"6  \" tab-index=\"0\">\n                                    <div class=\"highligth-row\">\n                                        <a href=\"https:\/\/www.ipsen.com\/germany\/press-releases\/asco-gu-2-jahres-follow-up-der-checkmate-9er-studie-anhaltender-behandlungsvorteil-unter-erstlinientherapie-des-fortgeschrittenen-nierenzellkarzinoms-mit-cabozantinib-plus-nivolumab-vs-sunitinib\/\"  aria-label=\"ASCO-GU: 2-Jahres-Follow-up der CheckMate-9ER-Studie: Anhaltender Behandlungsvorteil unter Erstlinientherapie des fortgeschrittenen Nierenzellkarzinoms mit Cabozantinib plus Nivolumab...\">\n                                            <div class=\"column-1\">\n                                                <div class=\"slim-standard-img\">\n                                                                                                                <a href=\"https:\/\/www.ipsen.com\/germany\/press-releases\/asco-gu-2-jahres-follow-up-der-checkmate-9er-studie-anhaltender-behandlungsvorteil-unter-erstlinientherapie-des-fortgeschrittenen-nierenzellkarzinoms-mit-cabozantinib-plus-nivolumab-vs-sunitinib\/\" >\n                                                                <img decoding=\"async\" src=\"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/sites\/6\/2023\/12\/06080352\/PR-final.jpg\" aria-label=\"ASCO-GU: 2-Jahres-Follow-up der CheckMate-9ER-Studie: Anhaltender Behandlungsvorteil unter Erstlinientherapie des fortgeschrittenen Nierenzellkarzinoms mit Cabozantinib plus Nivolumab...\" title=\"ASCO-GU: 2-Jahres-Follow-up der CheckMate-9ER-Studie: Anhaltender Behandlungsvorteil unter Erstlinientherapie des fortgeschrittenen Nierenzellkarzinoms mit Cabozantinib plus Nivolumab...\" >\n                                                            <\/a>\n                                                        \n                                                <\/div>\n                                            <\/div>\n                                        <\/a>\n                                        <a href=\"https:\/\/www.ipsen.com\/germany\/press-releases\/asco-gu-2-jahres-follow-up-der-checkmate-9er-studie-anhaltender-behandlungsvorteil-unter-erstlinientherapie-des-fortgeschrittenen-nierenzellkarzinoms-mit-cabozantinib-plus-nivolumab-vs-sunitinib\/\"  aria-label=\"ASCO-GU: 2-Jahres-Follow-up der CheckMate-9ER-Studie: Anhaltender Behandlungsvorteil unter Erstlinientherapie des fortgeschrittenen Nierenzellkarzinoms mit Cabozantinib plus Nivolumab...\">\n                                            <div class=\"column-2\">\n                                                <div class=\"slim-standard-content\">\n                                                    <div class=\"slim-standard-tab-sec\">\n                                                        <button class=\"btn small-btn grey-bg visible\" style=\"background-color:#2797d3;\"> Onkologie <\/button>\n                                                        <p class=\"date-time dark-grey visible\">  &#8211; 14 M\u00e4rz 2022 <\/p>\n                                                    <\/div>\n                                                    <div class=\"slim-standard-para-sec\">\n                                                        <p class=\"slim-standard-para primary-blue\">\n                                                            ASCO-GU: 2-Jahres-Follow-up der CheckMate-9ER-Studie: Anhaltender Behandlungsvorteil unter Erstlinientherapie des fortgeschrittenen Nierenzellkarzinoms mit Cabozantinib plus Nivolumab&#8230;                                                        <\/p>\n                                                    <\/div>\n                                                <\/div>\n                                            <\/div>\n                                        <\/a>\n\n                                        <\/div>\n                                <\/div>\n                                                        <div class=\"slim-standard-tab glider-slide left-7\" data-gslide=\"7  \" tab-index=\"0\">\n                                    <div class=\"highligth-row\">\n                                        <a href=\"https:\/\/www.ipsen.com\/germany\/press-releases\/ipsen-kuendigt-ruecknahme-des-zulassungsantrags-fuer-palovaroten-an-und-bestaetigt-die-absicht-einer-neueinreichung-nach-zusaetzlichen-datenanalysen\/\"  aria-label=\"Ipsen k\u00fcndigt R\u00fccknahme des Zulassungsantrags f\u00fcr Palovaroten an und best\u00e4tigt die Absicht einer Neueinreichung nach...\">\n                                            <div class=\"column-1\">\n                                                <div class=\"slim-standard-img\">\n                                                                                                                <a href=\"https:\/\/www.ipsen.com\/germany\/press-releases\/ipsen-kuendigt-ruecknahme-des-zulassungsantrags-fuer-palovaroten-an-und-bestaetigt-die-absicht-einer-neueinreichung-nach-zusaetzlichen-datenanalysen\/\" >\n                                                                <img decoding=\"async\" src=\"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/sites\/6\/2023\/12\/06080352\/PR-final.jpg\" aria-label=\"Ipsen k\u00fcndigt R\u00fccknahme des Zulassungsantrags f\u00fcr Palovaroten an und best\u00e4tigt die Absicht einer Neueinreichung nach...\" title=\"Ipsen k\u00fcndigt R\u00fccknahme des Zulassungsantrags f\u00fcr Palovaroten an und best\u00e4tigt die Absicht einer Neueinreichung nach...\" >\n                                                            <\/a>\n                                                        \n                                                <\/div>\n                                            <\/div>\n                                        <\/a>\n                                        <a href=\"https:\/\/www.ipsen.com\/germany\/press-releases\/ipsen-kuendigt-ruecknahme-des-zulassungsantrags-fuer-palovaroten-an-und-bestaetigt-die-absicht-einer-neueinreichung-nach-zusaetzlichen-datenanalysen\/\"  aria-label=\"Ipsen k\u00fcndigt R\u00fccknahme des Zulassungsantrags f\u00fcr Palovaroten an und best\u00e4tigt die Absicht einer Neueinreichung nach...\">\n                                            <div class=\"column-2\">\n                                                <div class=\"slim-standard-content\">\n                                                    <div class=\"slim-standard-tab-sec\">\n                                                        <button class=\"btn small-btn grey-bg visible\" style=\"background-color:#2797d3;\"> Onkologie <\/button>\n                                                        <p class=\"date-time dark-grey visible\">  &#8211; 13 August 2021 <\/p>\n                                                    <\/div>\n                                                    <div class=\"slim-standard-para-sec\">\n                                                        <p class=\"slim-standard-para primary-blue\">\n                                                            Ipsen k\u00fcndigt R\u00fccknahme des Zulassungsantrags f\u00fcr Palovaroten an und best\u00e4tigt die Absicht einer Neueinreichung nach&#8230;                                                        <\/p>\n                                                    <\/div>\n                                                <\/div>\n                                            <\/div>\n                                        <\/a>\n\n                                        <\/div>\n                                <\/div>\n                                                        <div class=\"slim-standard-tab glider-slide left-8\" data-gslide=\"8  \" tab-index=\"0\">\n                                    <div class=\"highligth-row\">\n                                        <a href=\"https:\/\/www.ipsen.com\/germany\/press-releases\/zusammen-fuer-neue-perspektiven-in-der-onkologie-ipsen-pharma-schreibt-erstmalig-den-innovation-for-patient-care-award-aus\/\"  aria-label=\"Zusammen f\u00fcr neue Perspektiven in der Onkologie: Ipsen Pharma schreibt erstmalig den Innovation for Patient...\">\n                                            <div class=\"column-1\">\n                                                <div class=\"slim-standard-img\">\n                                                                                                                <a href=\"https:\/\/www.ipsen.com\/germany\/press-releases\/zusammen-fuer-neue-perspektiven-in-der-onkologie-ipsen-pharma-schreibt-erstmalig-den-innovation-for-patient-care-award-aus\/\" >\n                                                                <img decoding=\"async\" src=\"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/sites\/6\/2023\/12\/06080352\/PR-final.jpg\" aria-label=\"Zusammen f\u00fcr neue Perspektiven in der Onkologie: Ipsen Pharma schreibt erstmalig den Innovation for Patient...\" title=\"Zusammen f\u00fcr neue Perspektiven in der Onkologie: Ipsen Pharma schreibt erstmalig den Innovation for Patient...\" >\n                                                            <\/a>\n                                                        \n                                                <\/div>\n                                            <\/div>\n                                        <\/a>\n                                        <a href=\"https:\/\/www.ipsen.com\/germany\/press-releases\/zusammen-fuer-neue-perspektiven-in-der-onkologie-ipsen-pharma-schreibt-erstmalig-den-innovation-for-patient-care-award-aus\/\"  aria-label=\"Zusammen f\u00fcr neue Perspektiven in der Onkologie: Ipsen Pharma schreibt erstmalig den Innovation for Patient...\">\n                                            <div class=\"column-2\">\n                                                <div class=\"slim-standard-content\">\n                                                    <div class=\"slim-standard-tab-sec\">\n                                                        <button class=\"btn small-btn grey-bg visible\" style=\"background-color:#5d6265;\"> Company <\/button>\n                                                        <p class=\"date-time dark-grey visible\">  &#8211; 10 August 2021 <\/p>\n                                                    <\/div>\n                                                    <div class=\"slim-standard-para-sec\">\n                                                        <p class=\"slim-standard-para primary-blue\">\n                                                            Zusammen f\u00fcr neue Perspektiven in der Onkologie: Ipsen Pharma schreibt erstmalig den Innovation for Patient&#8230;                                                        <\/p>\n                                                    <\/div>\n                                                <\/div>\n                                            <\/div>\n                                        <\/a>\n\n                                        <\/div>\n                                <\/div>\n                                                        <div class=\"slim-standard-tab glider-slide left-9\" data-gslide=\"9  \" tab-index=\"0\">\n                                    <div class=\"highligth-row\">\n                                        <a href=\"https:\/\/www.ipsen.com\/germany\/press-releases\/erste-potenzielle-therapie-zur-behandlung-der-seltenen-erkrankung-fibrodysplasia-ossificans-progressiva-fop-durch-den-wirkstoff-palovaroten-von-ipsen-in-der-beschleunigten-zulassungspruefung-in-den\/\"  aria-label=\"Erste potenzielle Therapie zur Behandlung der seltenen Erkrankung Fibrodysplasia ossificans progressiva (FOP) durch den Wirkstoff...\">\n                                            <div class=\"column-1\">\n                                                <div class=\"slim-standard-img\">\n                                                                                                                <a href=\"https:\/\/www.ipsen.com\/germany\/press-releases\/erste-potenzielle-therapie-zur-behandlung-der-seltenen-erkrankung-fibrodysplasia-ossificans-progressiva-fop-durch-den-wirkstoff-palovaroten-von-ipsen-in-der-beschleunigten-zulassungspruefung-in-den\/\" >\n                                                                <img decoding=\"async\" src=\"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/sites\/6\/2023\/12\/06080352\/PR-final.jpg\" aria-label=\"Erste potenzielle Therapie zur Behandlung der seltenen Erkrankung Fibrodysplasia ossificans progressiva (FOP) durch den Wirkstoff...\" title=\"Erste potenzielle Therapie zur Behandlung der seltenen Erkrankung Fibrodysplasia ossificans progressiva (FOP) durch den Wirkstoff...\" >\n                                                            <\/a>\n                                                        \n                                                <\/div>\n                                            <\/div>\n                                        <\/a>\n                                        <a href=\"https:\/\/www.ipsen.com\/germany\/press-releases\/erste-potenzielle-therapie-zur-behandlung-der-seltenen-erkrankung-fibrodysplasia-ossificans-progressiva-fop-durch-den-wirkstoff-palovaroten-von-ipsen-in-der-beschleunigten-zulassungspruefung-in-den\/\"  aria-label=\"Erste potenzielle Therapie zur Behandlung der seltenen Erkrankung Fibrodysplasia ossificans progressiva (FOP) durch den Wirkstoff...\">\n                                            <div class=\"column-2\">\n                                                <div class=\"slim-standard-content\">\n                                                    <div class=\"slim-standard-tab-sec\">\n                                                        <button class=\"btn small-btn grey-bg visible\" style=\"background-color:#7dc1e5;\"> Seltene Erkrankungen <\/button>\n                                                        <p class=\"date-time dark-grey visible\">  &#8211; 30 Juni 2021 <\/p>\n                                                    <\/div>\n                                                    <div class=\"slim-standard-para-sec\">\n                                                        <p class=\"slim-standard-para primary-blue\">\n                                                            Erste potenzielle Therapie zur Behandlung der seltenen Erkrankung Fibrodysplasia ossificans progressiva (FOP) durch den Wirkstoff&#8230;                                                        <\/p>\n                                                    <\/div>\n                                                <\/div>\n                                            <\/div>\n                                        <\/a>\n\n                                        <\/div>\n                                <\/div>\n                                                <\/div>\n                    <\/div>\n\n                <\/div><!--standard-carousel-over -->\n            <\/div><!--grid-div-over -->\n        <\/div>\n\n        <div class=\"slimcard-btn-sec\">\n                    <\/div>\n\n    <\/div>\n<\/div>\n           <\/div>\n        <\/div>\n    <\/section>\n\n\n<!-- Page Card Start -->\n<section class=\"text-tryo\">\n    <div class=\"container\" id=\"enable_heading_description\" data-alignment=\"Left\" data-enable_heading=\"1\"\n        data-enable_description=\"1\">\n\n                \n                <div class=\"row\">\n            <div class=\"col-lg-3 col-md-12  \">\n                <div class=\"sec-five-text\">\n                                    <h2 class=\"trayo-page-heading visible\">Das Engagement von Ipsen<\/h2>\n                                        <p class=\"trayo-page-summary visible\">Wir konzentrieren uns auf drei wichtige therapeutische Bereiche und setzen uns mit aller Kraft f\u00fcr die Behandlung unserer Patient*innen mit innovativen Arzneimitteln ein. <\/p>\n                <\/div>\n            <\/div>\n            <div class=\"col-lg-9 col-md-12 \">\n                <!-- Slider Start -->\n                                        <div class=\"text_tray_glider\">\n                                                        <a href=\"\/germany\/onkologie\/\"\n                                target=\"_self\">\n                                <div class=\"img-tray img-one\"\n                                    style='background-image:url(\"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/sites\/6\/2023\/11\/28132127\/04_1_HowWeHelpPeople_ONCOLOGY_Ronny_181204-209-1.jpg\");'>\n                                    <div class=\"tray\">\n                                        <div class=\"tray-inner\"\n                                            style=\"border-left: 5px solid #2797d3 ;\">\n                                            <p class=\"tray-heading-para\">Onkologie<\/p>\n                                            <p class=\"tray-para\">Seit 1986 entwickelt Ipsen Therapien f\u00fcr onkologische Erkrankungen. Heute umfasst unser Portfolio in Deutschland innovative Arzneimittel f\u00fcr die Behandlung von Patient*innen mit Prostatakrebs, Leberkrebs, neuroendokrinen Tumoren und Nierenzellkarzinom.<\/p>\n                                        <\/div>\n                                    <\/div>\n                                <\/div>\n                            <\/a>\n                                                        <a href=\"\/germany\/seltene-erkrankungen\/\"\n                                target=\"_self\">\n                                <div class=\"img-tray img-one\"\n                                    style='background-image:url(\"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/sites\/6\/2024\/08\/27191313\/Image20-1.jpg\");'>\n                                    <div class=\"tray\">\n                                        <div class=\"tray-inner\"\n                                            style=\"border-left: 5px solid #7dc1e5 ;\">\n                                            <p class=\"tray-heading-para\">Seltene Erkrankungen<\/p>\n                                            <p class=\"tray-para\">Bis heute sind ca. 98 Prozent der Rare Diseases nicht mit kausalen Therapien behandelbar. Unsere innovativen Medikamente f\u00fcr seltene Leber- und Knochenerkrankungen, Wachstumsst\u00f6rungen und Akromegalie schlie\u00dfen die entsprechenden Versorgungsl\u00fccken.<\/p>\n                                        <\/div>\n                                    <\/div>\n                                <\/div>\n                            <\/a>\n                                                        <a href=\"\/germany\/neurologie\/\"\n                                target=\"_self\">\n                                <div class=\"img-tray img-one\"\n                                    style='background-image:url(\"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/sites\/6\/2023\/11\/28133358\/04_3_HowWeHelpPeople_NEUROSCIENCE_Diana_ipsen-128-1.jpg\");'>\n                                    <div class=\"tray\">\n                                        <div class=\"tray-inner\"\n                                            style=\"border-left: 5px solid #a9d5ed ;\">\n                                            <p class=\"tray-heading-para\">Neurologie<\/p>\n                                            <p class=\"tray-para\">Mit unserer 30-j\u00e4hrigen Erfahrung in der Erforschung von Toxinen unterst\u00fctzen wir Kinder und Erwachsene mit schweren Bewegungsst\u00f6rungen, die die Autonomie und die Lebensqualit\u00e4t der Patient*innen erheblich beeintr\u00e4chtigen.<\/p>\n                                        <\/div>\n                                    <\/div>\n                                <\/div>\n                            <\/a>\n                                                    <\/div>\n                    <\/div>\n                <\/div>\n                <!-- Slider End -->\n            <\/div>\n        <\/div>\n                    <\/div>\n<\/section>\n\n<!-- Page Card End -->\n\n<!-- Ipsen Content Overlay Start -->\n<section class=\"two-col-image-section\">\n    <div class=\"container two-img-section-innner\">\n                <!-- Ipsen Content Overlay Variation Two Start -->\n                <div class=\"row \">\n                    <div class=\"col-xs-12 col-sm-12 col-md-6 column-1 \">\n                        <div id=\"image-carousel\" class=\"img-video-section carousel\" data-bs-ride=\"carousel\">\n                            <div class=\"carousel-inner\">\n                                                                        <div class=\"carousel-item active\">\n                                            <img decoding=\"async\" src=\"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/sites\/6\/2023\/11\/28133952\/05-01_PATIENTS_Text-and-Photos-Overlapped_181204-324_RONNY.jpg\" title=\"Image info\" alt=\"Image info\" >\n                                        <\/div>\n                                                                        <div class=\"carousel-item \">\n                                            <img decoding=\"async\" src=\"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/sites\/6\/2023\/11\/28134039\/05-05_PATIENTS_Text-and-Photos-Overlapped_20201011_6792-HD_LIU-GANG.jpg\" title=\"Image info\" alt=\"Image info\" >\n                                        <\/div>\n                                                                        <div class=\"carousel-item \">\n                                            <img decoding=\"async\" src=\"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/sites\/6\/2023\/11\/28134113\/05-06_PATIENTS_Text-and-Photos-Overlapped_526A1119_STEPHEN.jpg\" title=\"Image info\" alt=\"Image info\" >\n                                        <\/div>\n                                                                        <div class=\"carousel-item \">\n                                            <img decoding=\"async\" src=\"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/sites\/6\/2023\/11\/28134138\/05-07_PATIENTS_Text-and-Photos-Overlapped_Ipsen-Crewe-Steve-Pointon_079_STEVE.jpg\" title=\"Image info\" alt=\"Image info\" >\n                                        <\/div>\n                                                                        <div class=\"carousel-item \">\n                                            <img decoding=\"async\" src=\"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/sites\/6\/2023\/11\/28134152\/05-08_PATIENTS_Text-and-Photos-Overlapped_Misha-spastic-cerebral-palsy_237-HD_MISHA.jpg\" title=\"Image info\" alt=\"Image info\" >\n                                        <\/div>\n                                                            <\/div>\n                                                                    <div class=\"carousel-indicators\">\n                                                                                            <button type=\"button\" data-bs-target=\"#image-carousel\" data-bs-slide-to=\"0\"\n                                                    class=\"active\" aria-current=\"true\" aria-label=\"Slide 0\"><\/button>\n                                                                                            <button type=\"button\" data-bs-target=\"#image-carousel\" data-bs-slide-to=\"1\"\n                                                    class=\"active\" aria-current=\"true\" aria-label=\"Slide 1\"><\/button>\n                                                                                            <button type=\"button\" data-bs-target=\"#image-carousel\" data-bs-slide-to=\"2\"\n                                                    class=\"active\" aria-current=\"true\" aria-label=\"Slide 2\"><\/button>\n                                                                                            <button type=\"button\" data-bs-target=\"#image-carousel\" data-bs-slide-to=\"3\"\n                                                    class=\"active\" aria-current=\"true\" aria-label=\"Slide 3\"><\/button>\n                                                                                            <button type=\"button\" data-bs-target=\"#image-carousel\" data-bs-slide-to=\"4\"\n                                                    class=\"active\" aria-current=\"true\" aria-label=\"Slide 4\"><\/button>\n                                                                                    <\/div>\n                                                    <\/div>\n                    <\/div>\n                    <div class=\" col-xs-12 col-sm-12 col-md-6 column-2 \">\n                        <div class=\" section-content\">\n                                                                <div class=\"heading-dash\">\n                                        <span class=\"dash\"><\/span>\n                                        <p class=\"heading-para-right\">\n                                            Patient*innen                                         <\/p>\n                                    <\/div>\n                                                                                            <h3 class=\"section-head-two\">\n                                        Das Beste f\u00fcr ihre Gesundheit. Jeden Tag!                                     <\/h3>\n                                                                                            <p class=\"section-para \">\n                                        Ein besseres Leben f\u00fcr Menschen mit schweren Erkrankungen &#8211; das ist unser Ziel. Gemeinsam mit Vertreter*innen aus Patientenorganisationen, Wissenschaft, Medizin und Politik arbeiten wir daran, innovative Therapieoptionen zur Verf\u00fcgung zu stellen.                                     <\/p>\n                                                                                            <button role=\"link\" class=\"btn-link section-btn cta-visible\">\n                                        <a href=\"\/germany\/patienten\/\" aria-label=\"Learn more about Patient*innen \" target=\"_self\">\n                                            Mehr erfahren                                         <\/a>    \n                                    <\/button>\n                                                    <\/div>\n                    <\/div>\n                    <!-- Ipsen Content Overlay Variation Two End -->\n                <\/div>\n        <!-- Ipsen Content Overlay Variation two End -->\n            <\/div>\n<\/section>\n<!-- Ipsen Content Overlay End -->\n\n<!-- Text & Media Block Code -->\n<section class=\"two-col-section text-media-section\">\n    <div class=\"container two-section-innner section-reverse\">\n        <div class=\"response-inner\" style=\"background-image: url('')\">\n            <div class=\"row section-reverse\">\n                <div class=\"col-xs-12 col-sm-12 col-md-6\">\n                                                    <div class=\"img-video-section\">\n                                <img decoding=\"async\" src=\"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/sites\/6\/2023\/11\/28134238\/06-02_RESPONSIBILITY_iStock-1214243583_Text-and-Photos-Regular-Right-1.jpg\" alt=\"Verantwortung  \" title=\"Verantwortung  \">\n                            <\/div>\n                                        <\/div>\n                <div class=\" col-xs-12 col-sm-12 col-md-6\">\n                    <div class=\"section-content\">\n                        <div class=\"heading-dash\">\n                                                                <span class=\"dash\"><\/span>\n                                <p class=\"heading-para\">\n                                    Verantwortung                                  <\/p>\n                                                    <\/div>\n                        <p class=\"section-head-two\">\n                            F\u00fcr gesunde Perspektiven                          <\/p>\n                        <p><span class=\"TextRun SCXW123645210 BCX0\" lang=\"DE-DE\" xml:lang=\"DE-DE\" data-contrast=\"auto\"><span class=\"NormalTextRun SCXW123645210 BCX0\">Unsere Zukunft verantwortungsvoll gestalten: Das Engagement daf\u00fcr ist fest verankert in der Mission von Ipsen. W<\/span><span class=\"NormalTextRun SCXW123645210 BCX0\">ir <\/span><span class=\"NormalTextRun SCXW123645210 BCX0\">leben <\/span><span class=\"NormalTextRun SCXW123645210 BCX0\">eine Kultur der Verantwortung, die jeden Bereich unseres Unternehmens ber\u00fchrt. <\/span><span class=\"NormalTextRun SCXW123645210 BCX0\">Nachhaltiges Wirtschaften und gesellschaftliches Engagement <\/span><span class=\"NormalTextRun SCXW123645210 BCX0\">sind f\u00fcr uns selbstverst\u00e4ndlich.<\/span><\/span><span class=\"EOP SCXW123645210 BCX0\" data-ccp-props=\"{}\">\u00a0<\/span><\/p>\n                            \n                        <button aria-label=\"Learn more about Verantwortung  \" role=\"link\" class=\"btn-link section-btn cta-visible\"> \n                            <a aria-label=\"Learn more about\" href=\"\/germany\/verantwortung\/\" target=\"_self\"> Mehr erfahren  <\/a>\n                        <\/button>\n                        \n                    <\/div>\n                <\/div>\n            <\/div>\n        <\/div>\n    <\/div>\n<\/section>\n\n\n\n\n    <section class=\"title-text img-bg\">\n        <div class=\"container\">\n            <div class=\"title-text-inner\" style=\"background-image:url(https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/sites\/6\/2024\/05\/21153042\/Module-Careers_Banner-Home_1410x446pix-1.jpg)\">\n                <!-- If heading is enabled then it's visible -->\n                <div class=\"text-head-dash visible\">\n                                            <h2 class=\"heading-three\">\n                            Arbeiten bei Ipsen                         <\/h2>\n                                        \n                <\/div>\n\n                <!-- If subtitle is enabled then it's visible -->\n                <div class=\"text-head-dash hidden\">\n                                            <h3 class=\"heading-three\">\n                                                    <\/h3>\n                    \n                <\/div>\n                \n                <!-- If description is enabled then it's visible -->\n                <div class=\"text-parbase visible\">\n                    <p><p><span class=\"TextRun SCXW75788790 BCX0\" lang=\"DE-DE\" xml:lang=\"DE-DE\" data-contrast=\"auto\"><span class=\"NormalTextRun SCXW75788790 BCX0\">Es gibt viele gute Gr\u00fcnde, bei <\/span><span class=\"NormalTextRun SCXW75788790 BCX0\">Ipsen<\/span> <span class=\"NormalTextRun SCXW75788790 BCX0\">in Deutschland <\/span><span class=\"NormalTextRun SCXW75788790 BCX0\">zu arbeiten. <\/span><span class=\"NormalTextRun SCXW75788790 BCX0\">Neben einem spannenden T\u00e4tigkeitsfeld und optimalen <\/span><span class=\"NormalTextRun SCXW75788790 BCX0\">Rahmenbedingungen <\/span><span class=\"NormalTextRun SCXW75788790 BCX0\">engagierst<\/span><span class=\"NormalTextRun SCXW75788790 BCX0\"> Du <\/span><span class=\"NormalTextRun SCXW75788790 BCX0\">Dich <\/span><span class=\"NormalTextRun SCXW75788790 BCX0\">tagt\u00e4glich <\/span><span class=\"NormalTextRun SCXW75788790 BCX0\">f\u00fcr <\/span><span class=\"NormalTextRun SCXW75788790 BCX0\">eine <\/span><span class=\"NormalTextRun SCXW75788790 BCX0\">erf\u00fcllende Aufgabe <\/span><span class=\"NormalTextRun SCXW75788790 BCX0\">\u2013 denn wir <\/span><span class=\"NormalTextRun SCXW75788790 BCX0\">bei Ipsen <\/span><span class=\"NormalTextRun SCXW75788790 BCX0\">verbessern <\/span><span class=\"NormalTextRun SCXW75788790 BCX0\">mit unsere<\/span><span class=\"NormalTextRun SCXW75788790 BCX0\">m Verst\u00e4ndnis von<\/span><span class=\"NormalTextRun SCXW75788790 BCX0\"> Medizin <\/span><span class=\"NormalTextRun SCXW75788790 BCX0\">das Leben von Menschen mit <\/span><span class=\"NormalTextRun SCXW75788790 BCX0\">schweren und<\/span><span class=\"NormalTextRun SCXW75788790 BCX0\"> seltenen Krankheiten.\u00a0<\/span><\/span><span class=\"EOP SCXW75788790 BCX0\" data-ccp-props=\"{}\">\u00a0<\/span><\/p>\n<\/p>\n                <\/div>\n\n                <!-- If button is enabled then it's visible -->\n                                        <div class=\"btn-txt\">\n                            <button aria-label=\"Learn more about \" class=\"btn-link section-btn cta-visible\"  role=\"link\">\n                                <a href=\"\/germany\/arbeiten-bei-ipsen\/\" target=\"_self\">\n                                    Mehr erfahren                                 <\/a>\n                            <\/button>\n                        <\/div>\n                \n            <\/div>\n        <\/div>\n    <\/section>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-23","page","type-page","status-publish","hentry","entry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v22.5 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Ipsen | Innovative Arzneimittel f\u00fcr unsere Patient*innen<\/title>\n<meta name=\"description\" content=\"Ipsen entwickelt innovative Arzneimittel, die das Leben von Menschen mit schweren oder seltenen Erkrankungen verbessern.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.ipsen.com\/germany\/\" \/>\n<meta property=\"og:locale\" content=\"de_DE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ipsen | Innovative Arzneimittel f\u00fcr unsere Patient*innen\" \/>\n<meta property=\"og:description\" content=\"Ipsen entwickelt innovative Arzneimittel, die das Leben von Menschen mit schweren oder seltenen Erkrankungen verbessern.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.ipsen.com\/germany\/\" \/>\n<meta property=\"og:site_name\" content=\"Germany\" \/>\n<meta property=\"article:modified_time\" content=\"2024-10-10T11:10:58+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.ipsen.com\/germany\/\",\"url\":\"https:\/\/www.ipsen.com\/germany\/\",\"name\":\"Ipsen | Innovative Arzneimittel f\u00fcr unsere Patient*innen\",\"isPartOf\":{\"@id\":\"https:\/\/www.ipsen.com\/germany\/#website\"},\"datePublished\":\"2023-11-27T11:29:27+00:00\",\"dateModified\":\"2024-10-10T11:10:58+00:00\",\"description\":\"Ipsen entwickelt innovative Arzneimittel, die das Leben von Menschen mit schweren oder seltenen Erkrankungen verbessern.\",\"breadcrumb\":{\"@id\":\"https:\/\/www.ipsen.com\/germany\/#breadcrumb\"},\"inLanguage\":\"de\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.ipsen.com\/germany\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.ipsen.com\/germany\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.ipsen.com\/germany\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Home\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.ipsen.com\/germany\/#website\",\"url\":\"https:\/\/www.ipsen.com\/germany\/\",\"name\":\"Germany\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.ipsen.com\/germany\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.ipsen.com\/germany\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"de\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.ipsen.com\/germany\/#organization\",\"name\":\"Germany\",\"url\":\"https:\/\/www.ipsen.com\/germany\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\/\/www.ipsen.com\/germany\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/sites\/6\/2023\/12\/07165742\/Latest_Ipsen-logo_168x48.svg\",\"contentUrl\":\"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/sites\/6\/2023\/12\/07165742\/Latest_Ipsen-logo_168x48.svg\",\"caption\":\"Germany\"},\"image\":{\"@id\":\"https:\/\/www.ipsen.com\/germany\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Ipsen | Innovative Arzneimittel f\u00fcr unsere Patient*innen","description":"Ipsen entwickelt innovative Arzneimittel, die das Leben von Menschen mit schweren oder seltenen Erkrankungen verbessern.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.ipsen.com\/germany\/","og_locale":"de_DE","og_type":"article","og_title":"Ipsen | Innovative Arzneimittel f\u00fcr unsere Patient*innen","og_description":"Ipsen entwickelt innovative Arzneimittel, die das Leben von Menschen mit schweren oder seltenen Erkrankungen verbessern.","og_url":"https:\/\/www.ipsen.com\/germany\/","og_site_name":"Germany","article_modified_time":"2024-10-10T11:10:58+00:00","twitter_card":"summary_large_image","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.ipsen.com\/germany\/","url":"https:\/\/www.ipsen.com\/germany\/","name":"Ipsen | Innovative Arzneimittel f\u00fcr unsere Patient*innen","isPartOf":{"@id":"https:\/\/www.ipsen.com\/germany\/#website"},"datePublished":"2023-11-27T11:29:27+00:00","dateModified":"2024-10-10T11:10:58+00:00","description":"Ipsen entwickelt innovative Arzneimittel, die das Leben von Menschen mit schweren oder seltenen Erkrankungen verbessern.","breadcrumb":{"@id":"https:\/\/www.ipsen.com\/germany\/#breadcrumb"},"inLanguage":"de","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.ipsen.com\/germany\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.ipsen.com\/germany\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.ipsen.com\/germany\/"},{"@type":"ListItem","position":2,"name":"Home"}]},{"@type":"WebSite","@id":"https:\/\/www.ipsen.com\/germany\/#website","url":"https:\/\/www.ipsen.com\/germany\/","name":"Germany","description":"","publisher":{"@id":"https:\/\/www.ipsen.com\/germany\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.ipsen.com\/germany\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"de"},{"@type":"Organization","@id":"https:\/\/www.ipsen.com\/germany\/#organization","name":"Germany","url":"https:\/\/www.ipsen.com\/germany\/","logo":{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/www.ipsen.com\/germany\/#\/schema\/logo\/image\/","url":"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/sites\/6\/2023\/12\/07165742\/Latest_Ipsen-logo_168x48.svg","contentUrl":"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/sites\/6\/2023\/12\/07165742\/Latest_Ipsen-logo_168x48.svg","caption":"Germany"},"image":{"@id":"https:\/\/www.ipsen.com\/germany\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/www.ipsen.com\/germany\/wp-json\/wp\/v2\/pages\/23"}],"collection":[{"href":"https:\/\/www.ipsen.com\/germany\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.ipsen.com\/germany\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.ipsen.com\/germany\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.ipsen.com\/germany\/wp-json\/wp\/v2\/comments?post=23"}],"version-history":[{"count":77,"href":"https:\/\/www.ipsen.com\/germany\/wp-json\/wp\/v2\/pages\/23\/revisions"}],"predecessor-version":[{"id":2326,"href":"https:\/\/www.ipsen.com\/germany\/wp-json\/wp\/v2\/pages\/23\/revisions\/2326"}],"wp:attachment":[{"href":"https:\/\/www.ipsen.com\/germany\/wp-json\/wp\/v2\/media?parent=23"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}